The Cancer Letter

The Cancer Letter The Cancer Letter is an award-winning weekly newsletter covering cancer research funding, legislation Congress and the pharmaceutical industry.

The Cancer Letter, a weekly online publication, is the leading source of information on development of cancer therapies, cancer research funding and health care finance, legislation and policy. The Cancer Letter reaches the key opinion leaders in academic oncology and in the biotechnology and pharmaceutical industries. Our audience includes faculty and staff members at cancer centers, pharmaceutic

al and biotechnology companies, government agencies, and Wall Street professionals. Based in Washington, D.C., The Cancer Letter provides in-depth coverage of events at cancer centers, the National Cancer Institute, National Institutes of Health, Food & Drug Administration, U.S. Over the past four decades, The Cancer Letter has earned acclaim and numerous journalism awards for its investigative coverage of issues that shape oncology. Our work has been profiled and cited in The New York Times, The Washington Post, 60 Minutes, 20/20, CNN, NPR, Science, Nature and many other news outlets. Our coverage has triggered investigations by Congressional committees, the Institute of Medicine, the Federal Trade Commission, the Securities and Exchange Commission, and the Department of Justice. The Cancer Letter was founded in 1973 by journalist Jerry D. Boyd, two years after Congress passed the National Cancer Act of 1971. Boyd retired in 1990, turning over the company to his daughter Kirsten Boyd Goldberg, who served as editor and publisher for the next 20 years. Paul Goldberg became publisher in January 2011.

The Directors: Joann Sweasy and Robert Winn reflect on lessons learned during a tough yearFormer and current Association...
12/21/2025

The Directors: Joann Sweasy and Robert Winn reflect on lessons learned during a tough year
Former and current Association of American Cancer Institutes (AACI) presidents agree: strategic communication is key to safeguarding the future of cancer research
(Fred & Pamela Buffett Cancer Center, VCU Massey Comprehensive Cancer Center)Association of American Cancer Institutes (AACI)
https://cancerletter.com/podcastc/20251219_1/

Testing for asbestos in talc-based cosmetics seems like a no-brainer—why did FDA withdraw a rule to standardize it?Last ...
12/17/2025

Testing for asbestos in talc-based cosmetics seems like a no-brainer—why did FDA withdraw a rule to standardize it?

Last month, FDA withdrew a proposed rule for standardized asbestos testing in talc-based cosmetics. The proposed rule, introduced in Nov. 2024 and withdrawn Nov. 2025, was mandated by the Modernization of Cosmetics Regulation Act of 2022 or MoCRA.

Following an open comment period, FDA decided to withdraw the rule—citing significant public opposition and unintended consequences.

Last month, FDA withdrew a proposed rule for standardized asbestos testing in talc-based cosmetics. The proposed rule, introduced in Nov. 2024 and withdrawn Nov. 2025, was mandated by the Modernization of Cosmetics Regulation Act of 2022 or MoCRA. Following an open comment period, FDA decided to wit...

ESMO - European Society for Medical Oncology publishes guidances on AI tools for clinicians, patients, and researchersSa...
12/15/2025

ESMO - European Society for Medical Oncology publishes guidances on AI tools for clinicians, patients, and researchers
Says one author: “We think there should be some degree of human oversight, otherwise, they can go completely rogue and nobody notices.”
https://cancerletter.com/regulatory-news/20251212_3/

Address

Washington D.C., DC

Telephone

+12023621809

Website

Alerts

Be the first to know and let us send you an email when The Cancer Letter posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to The Cancer Letter:

Shortcuts

Share

Category